Researchers in Denmark conducted a prospective single-centre study including 160 patients with newly diagnosed high-risk prostate cancer between 2021 and 2024. All the participants first underwent an ...

A new radioactive diagnostic agent for use in prostate cancer has been approved by the US Food and Drug Administration (FDA). The product, Gallium 68 PSMA-11 (Ga 68 PSMA-11), has been approved for ...

177Lu-PSMA-617 combined with ADT and ARPI reduced progression or death risk by 28% in PSMA-positive mHSPC patients. The PSMAddition trial showed significant rPFS improvement and a positive OS trend, ...

The Alliance for Clinical Trials in Oncology has launched a randomized phase III clinical trial called RECIPROCAL (Alliance ...

Risk factors like Gleason score, cancer stage, PSA levels, and genetic markers guide prostate cancer treatment decisions. Treatment options include active surveillance, surgery, radiation, hormone ...

According to a new analysis, PLND does not impact recurrence-free survival but may reduce metastatic spread in intermediate- and high-risk prostate cancer. The benefit of PLND is most evident in ...

PYLCLARI® provides solutions to a wider patient group across Poland where there is high demand and unmet need PARIS, Dec. 23, ...

Dr. Nicholas James discusses why it is important to identify which patients with high-risk prostate cancer will truly benefit from intensified treatment. It is important to target intensified therapy ...

The U.S. Food and Drug Administration (FDA) on Friday approved Novartis AG’s (NYSE:NVS) Pluvicto for prostate cancer patients. The expanded indication, which approximately triples the number of ...